Efficacy of Virechana followed by Gomutra-haritaki in the fatty liver disease?
- Conditions
- Health Condition 1: K77- Liver disorders in diseases classified elsewhere
- Registration Number
- CTRI/2021/11/038277
- Lead Sponsor
- AD
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
•NAFLD confirmed by NFS score with or without having symptoms like fatigue, mild discomfort in the upper quadrant of abdomen etc.
•NAFLD patients who are refractive to standard drugs of treatment.
•Willing and able to participate in study and given written informed consent.
•Yogya for Virechana
•Excessive use of alcohol within 2 years prior to initial screening. Or alcohol intake more than 20g per day for female and less than 30 g per day for males
•Uncontrolled systemic disease or medically unstable and major psychological disorders
•Any dysfunction of liver besides non-alcoholic fatty liver disease like viral hepatitis liver parenchymal disease, ascites, portal hypertension, Hepato-cellular carcinoma, Auto- immune hepatitis, Primary biliary cirrhosis, Wilsons disease, and liver transplantation or any other conditions interfering with the result of the treatment Alcoholic fatty liver disease patient
•Pregnant/lactating female
•Virechana ayogya
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method